Insmed (INSM) Income from Continuing Operations (2010 - 2026)
Insmed's (INSM) quarterly Income from Continuing Operations came in at 163598000.0 in Q1 2026, up 36.24% year-on-year from 120083601.66 in Q1 2025, and up 50.19% quarter-over-quarter from 328434000.0 in Q4 2025.
Insmed (INSM) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Insmed's Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 163598000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 36.24% year-over-year to 163598000.0 in Q1 2026; TTM through Mar 2026 was 1183719000.0, a 16.82% decrease from a year earlier, with the FY2025 full-year figure at 1276749000.0, down 39.72% from the prior year.
- Income from Continuing Operations grew to 163598000.0 in Q1 2026 per INSM's latest filing, from 328434000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 94621000.0 in Q1 2022 and bottomed at 370001000.0 in Q3 2025.
- The 5-year median for Income from Continuing Operations is 186063000.0 (2023), against an average of 210890470.59.
- Across the five-year window, Income from Continuing Operations tumbled 155.92% in 2023 and jumped 36.24% in 2026, its largest moves.
- Year by year, Income from Continuing Operations stood at 160123000.0 in 2022, then decreased by 16.2% to 186063000.0 in 2023, then declined by 26.62% to 235589000.0 in 2024, then plunged by 39.41% to 328434000.0 in 2025, then soared by 50.19% to 163598000.0 in 2026.
- Per Business Quant, the three latest INSM Income from Continuing Operations figures stand at 163598000.0 (Q1 2026), 328434000.0 (Q4 2025), and 370001000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Insmed | 23.26 Bn | 22.03 Bn | 258.54 Mn | -163.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -163.60 Mn |
| Dec 31, 2025 | -328.43 Mn |
| Sep 30, 2025 | -370.00 Mn |
| Jun 30, 2025 | -321.69 Mn |
| Mar 31, 2025 | -256.57 Mn |
| Dec 31, 2024 | -235.59 Mn |
| Sep 30, 2024 | -220.52 Mn |
| Jun 30, 2024 | -300.57 Mn |
| Mar 31, 2024 | -157.09 Mn |
| Dec 31, 2023 | -186.06 Mn |
| Sep 30, 2023 | -158.93 Mn |
| Jun 30, 2023 | -244.78 Mn |
| Mar 31, 2023 | -159.76 Mn |
| Dec 31, 2022 | -160.12 Mn |
| Sep 30, 2022 | -131.15 Mn |
| Jun 30, 2022 | -95.65 Mn |
| Mar 31, 2022 | -94.62 Mn |
| Dec 31, 2021 | -112.94 Mn |
| Sep 30, 2021 | -112.71 Mn |
| Jun 30, 2021 | -117.30 Mn |